Trial results

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07139548 on ClinicalTrials.gov · last registry update 2025-08-24

Registered but not yet open, with 600 participants planned. Due to report 1 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Guangdong Raynovent Biotech Co., Ltd

Sponsor type

Industry

Enrollment

600

Started

2025-08-31

Primary completion

2026-12-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)

Conditions studied

T2DM

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.